Pictilisib Chemical Properties

Melting point:

>200oC (dec.)

Density 

1.53±0.1 g/cm3(Predicted)

storage temp. 

-20°C

solubility 

Soluble in DMSO (>25 mg/ml)

form 

White powder solid.

pka

12.22±0.40(Predicted)

color 

White/off-white

Stability:

Stable for 1 year from date of purchase as supplied. Solutions in DMSO may be stored at -20°C for up to 3 months.

Safety Information

HS Code 

29350090

Pictilisib Usage And Synthesis

Description

GDC-0941/Pictilisib (957054-30-7) is a potent and selective inhibitor of class I phosphatidylinositol-3-kinases (PI3K) with significant antitumor activity – IC50’s: PI3Kα = 3nM, PI3Kβ = 33 nM, PI3Kδ = 3 nM, PI3Kγ = 75 nM.1,2?? GDC-0941 is the chemical probe of choice for the pan-inhibition of class I PI3K’s.3?Currently in clinical trials.4

Uses

GDC-0941 is a potent and selective oral inhibitor of the class I PI3K. GDC-0941 demonstrated broad spectrum of activity in breast, ovarian, lung, and prostate cancer models. Studies has also shown GDC-0941 may enhance anti-tumor activity of Docetaxel (D494420) in human breast cancer models. Potent PI3K inhibitor.

Definition

ChEBI: A sulfonamide composed of indazole, morpholine, and methylsulfonyl-substituted piperazine rings bound to a thienopyrimidine ring.

target

PI3Kα

References

1) Folkes?et al.?(2008),?The identification of 2-(1H-indazol-4-yl)-6-(4-methanesulfonyl-piperazin-1-ylmethyl)-4-morpholin-4-yl-thieno[3,2-d]pyrimidine(GDC-0941) as a potent, selective, orally bioavailable inhibitor of class I PI3 kinase for the treatment of cancer;? J.?Med. Chem.,?51?5522 2) Raynaud?et al. (2009),?Biological properties of potent inhibitors of class I phosphatidylinositide 3-kinase: from PI-103 through PI-540, PI620 to the oral agent GDC-0941; Mol. Cancer Ther.,?8?1725 3) Knapp et al. (2013),?A public-private partnership to unlock the untargeted kinome; Nat. Chem. Biol.,?9?3 4) Sarker?et al. (2015),?First-in-human phase I study of pictilisib (GDC-0941), a potent pan-class I phosphatidylinositol-3-kinase (PI3K) inhibitor, in patients with advanced solid tumors; Clin. Cancer Res.,?21?77

Pictilisib(957054-30-7)Related Product Information

• Motesanib
• DL-Malic acid
• Everolimus
• MK-2206 2HCl
• CAL-101
• Trametinib
• PLX4032
• BEZ235 (NVP-BEZ235, Dactolisib)
• 2-[(6-Amino-9H-purin-9-yl)methyl]-5-methyl-3-(2-methylphenyl)-4(3H)-quinazolinone
• N-[4-[5-(1,3-BENZODIOXOL-5-YL)-3-METHOXY-1H-1,2,4-TRIAZOL-1-YL]PHENYL]-2-(PHENYLTHIO)ACETAMIDE
• NSC 23766 TETRAHYDROCHLORIDE
• NSC697923
• MIF Antagonist, ISO-1
• GSK-3β Inhibitor XVIII
• JNJ-10198409
• Compound 23
• ERK Inhibitor
• 6-HYDROXY-2,5,7,8-TETRAMETHYLCHROMAN-2-CARBOXYLIC ACID